These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 1726189

  • 21. 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys.
    Insel TR, Battaglia G, Johannessen JN, Marra S, De Souza EB.
    J Pharmacol Exp Ther; 1989 Jun; 249(3):713-20. PubMed ID: 2471824
    [Abstract] [Full Text] [Related]

  • 22. Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones.
    Sanchez V, O'shea E, Saadat KS, Elliott JM, Colado MI, Green AR.
    J Psychopharmacol; 2004 Sep; 18(3):412-6. PubMed ID: 15358986
    [Abstract] [Full Text] [Related]

  • 23. A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives.
    Stone DM, Johnson M, Hanson GR, Gibb JW.
    Eur J Pharmacol; 1987 Feb 10; 134(2):245-8. PubMed ID: 2883012
    [Abstract] [Full Text] [Related]

  • 24. 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine.
    Colado MI, Murray TK, Green AR.
    Br J Pharmacol; 1993 Mar 10; 108(3):583-9. PubMed ID: 7682129
    [Abstract] [Full Text] [Related]

  • 25. Effect of 3,4-methylenedioxymethamphetamine on [3H]paroxetine binding in the frontal cortex and blood platelets of rats.
    Nash JF, Arora RC, Schreiber MA, Meltzer HY.
    Biochem Pharmacol; 1991 Jan 01; 41(1):79-84. PubMed ID: 1702633
    [Abstract] [Full Text] [Related]

  • 26. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine.
    Schmidt CJ.
    J Pharmacol Exp Ther; 1987 Jan 01; 240(1):1-7. PubMed ID: 2433425
    [Abstract] [Full Text] [Related]

  • 27. Behavioral, biochemical and neurotoxicological actions of the alpha-ethyl homologue of p-chloroamphetamine.
    Johnson MP, Huang XM, Oberlender R, Nash JF, Nichols DE.
    Eur J Pharmacol; 1990 Nov 20; 191(1):1-10. PubMed ID: 1982656
    [Abstract] [Full Text] [Related]

  • 28. [3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues.
    Johnson MP, Conarty PF, Nichols DE.
    Eur J Pharmacol; 1991 Jul 23; 200(1):9-16. PubMed ID: 1685125
    [Abstract] [Full Text] [Related]

  • 29. 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose.
    Esteban B, O'Shea E, Camarero J, Sanchez V, Green AR, Colado MI.
    Psychopharmacology (Berl); 2001 Mar 23; 154(3):251-60. PubMed ID: 11351932
    [Abstract] [Full Text] [Related]

  • 30. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I, Youdim MB, Finberg JP.
    J Neurochem; 1996 Oct 23; 67(4):1532-9. PubMed ID: 8858937
    [Abstract] [Full Text] [Related]

  • 31. 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine.
    McKenna DJ, Guan XM, Shulgin AT.
    Pharmacol Biochem Behav; 1991 Mar 23; 38(3):505-12. PubMed ID: 1829838
    [Abstract] [Full Text] [Related]

  • 32. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.
    Colado MI, Williams JL, Green AR.
    Br J Pharmacol; 1995 Aug 23; 115(7):1281-9. PubMed ID: 7582557
    [Abstract] [Full Text] [Related]

  • 33. Mice lacking multidrug resistance protein 1a show altered dopaminergic responses to methylenedioxymethamphetamine (MDMA) in striatum.
    Scheidweiler KB, Ladenheim B, Cadet JL, Huestis MA.
    Neurotox Res; 2010 Aug 23; 18(2):200-9. PubMed ID: 19851718
    [Abstract] [Full Text] [Related]

  • 34. Reduction of [3H]6-nitroquipazine-labelled 5-hydroxytryptamine uptake sites in rat brain by 3,4-methylenedioxymethamphetamine.
    Hashimoto K, Goromaru T.
    Fundam Clin Pharmacol; 1990 Aug 23; 4(6):635-41. PubMed ID: 1710592
    [Abstract] [Full Text] [Related]

  • 35. Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain.
    Steele TD, Nichols DE, Yim GK.
    Biochem Pharmacol; 1987 Jul 15; 36(14):2297-303. PubMed ID: 2886126
    [Abstract] [Full Text] [Related]

  • 36. Effects of N-ethyl-3,4-methylenedioxyamphetamine (MDE) on central serotonergic and dopaminergic systems of the rat.
    Johnson M, Hanson GR, Gibb JW.
    Biochem Pharmacol; 1987 Dec 01; 36(23):4085-93. PubMed ID: 2446629
    [Abstract] [Full Text] [Related]

  • 37. Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity.
    Brodkin J, Malyala A, Nash JF.
    Pharmacol Biochem Behav; 1993 Jul 01; 45(3):647-53. PubMed ID: 8101380
    [Abstract] [Full Text] [Related]

  • 38. Behavioral and neurochemical effects of chronic methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys.
    Frederick DL, Ali SF, Slikker W, Gillam MP, Allen RR, Paule MG.
    Neurotoxicol Teratol; 1995 Jul 01; 17(5):531-43. PubMed ID: 8551999
    [Abstract] [Full Text] [Related]

  • 39. Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
    Nichols DE, Brewster WK, Johnson MP, Oberlender R, Riggs RM.
    J Med Chem; 1990 Feb 01; 33(2):703-10. PubMed ID: 1967651
    [Abstract] [Full Text] [Related]

  • 40. Repeated administration of the substituted amphetamine p-methoxyamphetamine produces reductions in cortical 5-HT transporter binding but not 5-HT content, unlike 3,4-methylenedioxyamethamphetamine.
    Callaghan PD, Farrand K, Salem A, Hughes P, Daws LC, Irvine RJ.
    Eur J Pharmacol; 2006 Sep 28; 546(1-3):74-81. PubMed ID: 16925993
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.